NASDAQ:ARRY - Array Biopharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $14.72 -0.58 (-3.79 %) (As of 09/25/2018 02:40 AM ET)Previous Close$15.30Today's Range$14.61 - $15.3152-Week Range$9.98 - $20.21Volume3.04 million shsAverage Volume2.94 million shsMarket Capitalization$3.26 billionP/E Ratio-20.16Dividend YieldN/ABeta1.13 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation. The company's lead clinical programs include encorafenib and binimetinib that are investigated in approximately 30 clinical trials for various solid tumor indications, including a Phase III trial in BRAF-mutant colorectal cancer. Its product pipeline also includes ipatasertib, an AKT inhibitor that is in Phase III trial to treat prostate or breast cancers; selumetinib, a MEK inhibitor for cancer; larotrectinib, a PanTrk inhibitor that is in a Phase II/registration clinical trial for cancer; tucatinib, a HER2 inhibitor for breast cancer, which is in Phase II/registration trial; and ARRY-797 that is in Phase III clinical trial for Lamin A/C-related dilated cardiomyopathy. In addition, the company is developing varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric cancer; ARRY-382, a CSF1R inhibitor that is in Phase II clinical trial to treat cancer; motolimod/VTX-2337, a Toll-like receptor that is in Phase II clinical trial for cancer; and prexasertib/LY2606368, a CHK-1 inhibitor, which is in multiple Phase I or II clinical trials for cancer. Further, its drug candidates in Phase I clinical trials include GDC-0575, a CHK-1 inhibitor for cancer; LOXO-292, a RET inhibitor to treat cancer; and LOXO-195, a Trk inhibitor for cancer. Additionally, its drug candidates include Ganovo/danoprevir, a protease inhibitor for hepatitis C virus. The company was founded in 1998 and is headquartered in Boulder, Colorado. Receive ARRY News and Ratings via Email Sign-up to receive the latest news and ratings for ARRY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:ARRY CUSIP04269X10 Webwww.arraybiopharma.com Phone303-381-6600 Debt Debt-to-Equity Ratio0.42 Current Ratio4.71 Quick Ratio4.71 Price-To-Earnings Trailing P/E Ratio-20.16 Forward P/E Ratio-20.44 P/E GrowthN/A Sales & Book Value Annual Sales$173.77 million Price / Sales18.04 Cash FlowN/A Price / CashN/A Book Value$1.04 per share Price / Book14.15 Profitability EPS (Most Recent Fiscal Year)($0.73) Net Income$-147,340,000.00 Net Margins-84.79% Return on Equity-80.54% Return on Assets-33.50% Miscellaneous Employees298 Outstanding Shares212,920,000Market Cap$3.26 billion Array Biopharma (NASDAQ:ARRY) Frequently Asked Questions What is Array Biopharma's stock symbol? Array Biopharma trades on the NASDAQ under the ticker symbol "ARRY." How were Array Biopharma's earnings last quarter? Array Biopharma Inc (NASDAQ:ARRY) announced its quarterly earnings results on Tuesday, August, 14th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.01. The biopharmaceutical company had revenue of $35.40 million for the quarter, compared to the consensus estimate of $38.73 million. Array Biopharma had a negative net margin of 84.79% and a negative return on equity of 80.54%. Array Biopharma's quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.17) earnings per share. View Array Biopharma's Earnings History. When is Array Biopharma's next earnings date? Array Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for Array Biopharma. What price target have analysts set for ARRY? 8 brokerages have issued 1 year price targets for Array Biopharma's shares. Their predictions range from $13.00 to $33.00. On average, they anticipate Array Biopharma's stock price to reach $23.5714 in the next year. This suggests a possible upside of 60.1% from the stock's current price. View Analyst Price Targets for Array Biopharma. What is the consensus analysts' recommendation for Array Biopharma? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Array Biopharma in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Array Biopharma. What are Wall Street analysts saying about Array Biopharma stock? Here are some recent quotes from research analysts about Array Biopharma stock: 1. According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (8/17/2018) 2. Cantor Fitzgerald analysts commented, ". We maintain an Overweight rating with an updated $26 PT on ARRY shares. The company has an upcoming PDUFA of 6/30/18 for the combination of binimetinib/encorafenib (bini/enco), which, based on the results of the COLUMBUS study, has the potential to be best-in-class and take a market-leader position, in our view. In addition, we see further opportunity in BRAF+ CRC based on the safety lead-in portion data presented to date from the BEACON-CRC study." (6/24/2018) Who are some of Array Biopharma's key competitors? Some companies that are related to Array Biopharma include Ono Pharmaceutical (OPHLF), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Alnylam Pharmaceuticals (ALNY), Beigene (BGNE), Bausch Health Companies (BHC), Valeant Pharmaceuticals (VRX), Amneal Pharmaceuticals (AMRX), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Alkermes (ALKS) and Catalent (CTLT). Who are Array Biopharma's key executives? Array Biopharma's management team includes the folowing people: Mr. Ron Squarer, CEO & Director (Age 51)Mr. Jason Haddock, Chief Financial Officer (Age 48)Mr. Andrew R. Robbins, Chief Operating Officer (Age 42)Mr. Curtis G. Oltmans, Exec. VP, Gen. Counsel & Sec. (Age 55)Dr. Victor Sandor, Chief Medical Officer (Age 52) Who are Array Biopharma's major shareholders? Array Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (11.58%), FMR LLC (11.52%), BlackRock Inc. (8.03%), Morgan Stanley (1.70%), American Century Companies Inc. (1.24%) and Northern Trust Corp (1.19%). Company insiders that own Array Biopharma stock include Andrew R Robbins, Charles M Baum, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Redmile Group, Llc, Ron Squarer and Victor Sandor. View Institutional Ownership Trends for Array Biopharma. Which institutional investors are selling Array Biopharma stock? ARRY stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., United Services Automobile Association, Wells Fargo & Company MN, BNP Paribas Arbitrage SA, International Biotechnology Trust PLC, BlueMountain Capital Management LLC, Handelsbanken Fonder AB and MetLife Investment Advisors LLC. Company insiders that have sold Array Biopharma company stock in the last year include Andrew R Robbins, Charles M Baum, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Ron Squarer and Victor Sandor. View Insider Buying and Selling for Array Biopharma. Which institutional investors are buying Array Biopharma stock? ARRY stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, American Century Companies Inc., BlackRock Inc., Voya Investment Management LLC, FMR LLC, FMR LLC, First Light Asset Management LLC and Columbus Circle Investors. View Insider Buying and Selling for Array Biopharma. How do I buy shares of Array Biopharma? Shares of ARRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Array Biopharma's stock price today? One share of ARRY stock can currently be purchased for approximately $14.72. How big of a company is Array Biopharma? Array Biopharma has a market capitalization of $3.26 billion and generates $173.77 million in revenue each year. The biopharmaceutical company earns $-147,340,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. Array Biopharma employs 298 workers across the globe. What is Array Biopharma's official website? The official website for Array Biopharma is http://www.arraybiopharma.com. How can I contact Array Biopharma? Array Biopharma's mailing address is 3200 Walnut Street, Boulder CO, 80301. The biopharmaceutical company can be reached via phone at 303-381-6600 or via email at [email protected] MarketBeat Community Rating for Array Biopharma (NASDAQ ARRY)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 397 (Vote Outperform)Underperform Votes: 234 (Vote Underperform)Total Votes: 631MarketBeat's community ratings are surveys of what our community members think about Array Biopharma and other stocks. Vote "Outperform" if you believe ARRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARRY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/25/2018 by MarketBeat.com StaffFeatured Article: Why do companies issue stock splits?